Commonwealth of Pennsylvania Public School Empls Retrmt SYS Sells 6,003 Shares of Edwards Lifesciences Corporation $EW

Commonwealth of Pennsylvania Public School Empls Retrmt SYS decreased its position in Edwards Lifesciences Corporation (NYSE:EW) by 4.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 134,981 shares of the medical research company’s stock after selling 6,003 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Edwards Lifesciences were worth $11,507,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Norges Bank bought a new position in Edwards Lifesciences in the 4th quarter worth about $803,686,000. Eurizon Capital SGR S.p.A. bought a new position in Edwards Lifesciences in the 4th quarter worth about $13,694,000. Fideuram Asset Management Ireland dac bought a new position in Edwards Lifesciences in the 4th quarter worth about $572,000. National Pension Service lifted its stake in Edwards Lifesciences by 1.2% during the 4th quarter. National Pension Service now owns 935,283 shares of the medical research company’s stock valued at $79,733,000 after acquiring an additional 11,524 shares during the period. Finally, Weaver Consulting Group lifted its stake in Edwards Lifesciences by 2.6% during the 4th quarter. Weaver Consulting Group now owns 47,567 shares of the medical research company’s stock valued at $4,055,000 after acquiring an additional 1,198 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE EW opened at $88.33 on Tuesday. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $89.14. The firm has a market capitalization of $50.86 billion, a P/E ratio of 46.98, a PEG ratio of 2.17 and a beta of 0.87. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average price of $81.85 and a 200-day moving average price of $83.02.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Activity

In related news, VP Daniel J. Lippis sold 620 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $81.14, for a total value of $50,306.80. Following the completion of the sale, the vice president directly owned 40,411 shares of the company’s stock, valued at approximately $3,278,948.54. This represents a 1.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at $3,177,507.96. This represents a 24.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 95,057 shares of company stock valued at $7,874,217. 0.31% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on EW. Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the company an “outperform” rating in a research note on Monday, April 13th. Evercore restated an “outperform” rating and set a $93.00 target price on shares of Edwards Lifesciences in a research note on Friday, April 24th. The Goldman Sachs Group restated a “buy” rating and set a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Wells Fargo & Company upped their target price on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Finally, Robert W. Baird upped their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $95.65.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.